- Home
- PAI vs RLMD Comparison
PAI vs RLMD Comparison
Compare PAI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAI
- RLMD
- Stock Information
- Founded
- PAI 1973
- RLMD 2004
- Country
- PAI United States
- RLMD United States
- Employees
- PAI N/A
- RLMD N/A
- Industry
- PAI Trusts Except Educational Religious and Charitable
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- PAI Finance
- RLMD Health Care
- Exchange
- PAI Nasdaq
- RLMD Nasdaq
- Market Cap
- PAI 118.3M
- RLMD 110.6M
- IPO Year
- PAI N/A
- RLMD N/A
- Fundamental
- Price
- PAI $12.34
- RLMD $0.36
- Analyst Decision
- PAI
- RLMD Hold
- Analyst Count
- PAI 0
- RLMD 4
- Target Price
- PAI N/A
- RLMD $4.25
- AVG Volume (30 Days)
- PAI 25.0K
- RLMD 2.1M
- Earning Date
- PAI 01-01-0001
- RLMD 11-07-2024
- Dividend Yield
- PAI 4.78%
- RLMD N/A
- EPS Growth
- PAI N/A
- RLMD N/A
- EPS
- PAI N/A
- RLMD N/A
- Revenue
- PAI N/A
- RLMD N/A
- Revenue This Year
- PAI N/A
- RLMD N/A
- Revenue Next Year
- PAI N/A
- RLMD N/A
- P/E Ratio
- PAI N/A
- RLMD N/A
- Revenue Growth
- PAI N/A
- RLMD N/A
- 52 Week Low
- PAI $10.59
- RLMD $0.34
- 52 Week High
- PAI $12.63
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- PAI 37.60
- RLMD 17.00
- Support Level
- PAI $12.57
- RLMD $0.34
- Resistance Level
- PAI $12.72
- RLMD $0.40
- Average True Range (ATR)
- PAI 0.18
- RLMD 0.09
- MACD
- PAI -0.04
- RLMD -0.02
- Stochastic Oscillator
- PAI 5.13
- RLMD 0.72
About PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed primarily as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.